Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
69 hedge funds and large institutions have $171M invested in Albireo Pharma Inc in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 12 reducing their positions, and 11 closing their positions.
1,354% more call options, than puts
Call options by funds: $2.81M | Put options by funds: $193K
208% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 12
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
1% less funds holding
Funds holding: 70 → 69 (-1)
25% less capital invested
Capital invested by funds: $229M → $171M (-$58.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.5M |
| 2 |
CC
Chicago Capital
Chicago,
Illinois
|
+$6.98M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.66M |
| 4 |
PA
Perceptive Advisors
New York
|
+$5.62M |
| 5 |
AG
Artal Group
Luxembourg
|
+$3.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$12.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.17M |
| 3 |
Man Group
London,
United Kingdom
|
-$2.39M |
| 4 |
Squarepoint
New York
|
-$560K |
| 5 |
D.E. Shaw & Co
New York
|
-$438K |
ALBO Hedge Fund Activity: Q1 2020 in Review
69 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2020, worth a combined $171M — down 25% from $229M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ALBO and 10 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 37 added.
The largest buyer was Federated Hermes, adding an estimated $10.5M. The largest seller was TPG Group Holdings (SBS) Advisors, exiting entirely with an estimated $12.4M sold.
- 69 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2020, down from 70 in Q4 2019.
- Funds reported $171M of Albireo Pharma Inc stock for Q1 2020, down 25% quarter-over-quarter.
- 10 funds opened new Albireo Pharma Inc positions in Q1 2020 and 11 closed out, a net change of -1 holder.
- The largest Albireo Pharma Inc buyer in Q1 2020 was Federated Hermes, an estimated $10.5M added.
- The largest Albireo Pharma Inc seller in Q1 2020 was TPG Group Holdings (SBS) Advisors, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2020.